Vanguard Group
AVIR icon

Vanguard Group’s Atea Pharmaceuticals AVIR Stock Holding History

Vanguard Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$15.1M Sell
4,227,110
-482,165
-10% -$1.53M ﹤0.01% 2755
2025
Q3 		$13.7M Sell
4,709,275
-177,946
-4% -$608K ﹤0.01% 2809
2025
Q2 		$17.6M Buy
4,887,221
+159,519
+3% +$476K ﹤0.01% 2614
2025
Q1 		$14.1M Buy
4,727,702
+60,848
+1% +$190K ﹤0.01% 2664
2024
Q4 		$15.6M Sell
4,666,854
-184,364
-4% -$613K ﹤0.01% 2709
2024
Q3 		$16.3M Buy
4,851,218
+126,813
+3% +$460K ﹤0.01% 2701
2024
Q2 		$15.6M Buy
4,724,405
+1,883
+0% +$7.02K ﹤0.01% 2690
2024
Q1 		$19.1M Buy
4,722,522
+122,812
+3% +$481K ﹤0.01% 2626
2023
Q4 		$14M Buy
4,599,710
+26,270
+0.6% +$79.6K ﹤0.01% 2768
2023
Q3 		$13.7M Buy
4,573,440
+55,841
+1% +$190K ﹤0.01% 2705
2023
Q2 		$16.9M Sell
4,517,599
-69,582
-2% -$260K ﹤0.01% 2665
2023
Q1 		$15.4M Sell
4,587,181
-1,502,341
-25% -$6.09M ﹤0.01% 2716
2022
Q4 		$29.3M Sell
6,089,522
-1,494,734
-20% -$7.56M ﹤0.01% 2449
2022
Q3 		$43.2M Buy
7,584,256
+403,971
+6% +$3.09M ﹤0.01% 2254
2022
Q2 		$51M Buy
7,180,285
+451,082
+7% +$3.08M ﹤0.01% 2187
2022
Q1 		$48.6M Buy
6,729,203
+947,321
+16% +$6.43M ﹤0.01% 2321
2021
Q4 		$51.7M Buy
5,781,882
+601,927
+12% +$9.38M ﹤0.01% 2330
2021
Q3 		$182M Buy
5,179,955
+643,792
+14% +$17.9M ﹤0.01% 1666
2021
Q2 		$97.4M Buy
4,536,163
+3,429,258
+310% +$103M ﹤0.01% 2013
2021
Q1 		$68.4M Buy
1,106,905
+22,378
+2% +$1.51M ﹤0.01% 2137
2020
Q4 		$45.3M Buy
+1,084,527
New +$35M ﹤0.01% 2253

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group's AVIR Position: Q4 2025 in Review

Vanguard Group reduced its Atea Pharmaceuticals (AVIR) stake by 10% in Q4 2025, selling an estimated $1.53M and leaving 4,227,110 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2755.

Vanguard Group first reported a position in AVIR in Q4 2020 and has held it in 21 quarters since. The position peaked at $182M in Q3 2021. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

  • Vanguard Group held 4,227,110 shares of Atea Pharmaceuticals worth $15.1M as of Q4 2025.
  • Vanguard Group sold 482,165 Atea Pharmaceuticals shares in Q4 2025, an estimated $1.53M.
  • Atea Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2755 holding.
  • Vanguard Group first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's Atea Pharmaceuticals position peaked at $182M in Q3 2021.
  • 111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.